45
HEART FAILURE RESEARCH
Physicians on the medical staff participate in various heart failure trials and publications throughout the year that pave the way for the future of medicine . In fiscal year 2022 , the advanced heart failure team participated in 34 active trials and 42 peer-reviewed publications . Baylor Dallas was also a top ten enroller in seven studies , received five grants and had 43 podium presentations .
Grants awarded
The Variability of Donor-Derived Cell-Free DNA After Heart Transplantation . Principal investigator : Timothy Gong , MD , FACC .
Impact of Virus Infection on Donor-Derived Cell-Free DNA After Heart Transplantation Program . Principal investigator : Amit Alam , MD .
Feasibility of Bicarbonate-Based Purge Fluid in Abiomed Impella ® Device Implantation . Principal investigator : Cesar Guerrero-Miranda , MD , FACC , FHFSA .
Single-transcript sequencing of heart-transplantrelated acute hepatitis C infection : A single-patient extension of TROJAN-C to gather pilot data in support of future NIH grant application . Principal investigator : Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA .
COVID-19 Critical Care Consortium : Cardiac Sub-Study . Principal investigator : Dan Meyer , MD .
New England Journal of Medicine publication
Advanced heart failure and transplant cardiologists on the medical staff at Baylor University Medical Center are contributing on innovative clinical trials for COVID-19 . The following publication , led by Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA , an advanced heart failure cardiologist on the medical staff at Baylor University Medical Center , was featured in the New England Journal of Medicine in January 2022 .
Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients We conducted a randomized , double-blind , placebocontrolled trial involving non-hospitalized patients with COVID-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression ( age ≥60 years , obesity , or certain coexisting medical conditions ). Among non-hospitalized patients who were at high risk for COVID-19 progression , a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87 % lower risk of hospitalization or death than placebo .
Key clinical trials FY22
# 3 Enroller Worldwide
ARRAY-797-301 - A phase 3 , multinational , randomized , placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin a / c gene mutation . Principal investigator : Robert Gottlieb , MD , PhD , FACC , FAST , FIDSA .
# 5 Enroller Worldwide
GUARDIAN REGISTRY - Global utilization and registry database for improved heart preservation ( GUARDIAN ). Principal investigator : Dan Meyer , MD .
# 3 Enroller in the US
HELIOS-A - A phase 3 global , controlled , open-label study to evaluate the efficacy and safety of ALN-TTRSC02 in patients with hereditary transthyretin amyloidosis ( hATTR amyloidosis ). Principal investigator : Parag Kale , MD , FACC , FHFSA .
AIM-HIGHer - Assessment of implantable cardiac contractility modulation ( CCM ) in the heart failure group with higher ejection fraction . Principal investigator : Amarinder Bindra , MD .
rest - Prospective non-randomized post market study collecting clinical data on safety and effectiveness of the remedē ® System . Principal investigator : Parag Kale , MD , FACC , FHFSA .
TRIFECTA - Trifecta-Heart Study : Comparing the ddcfDNA test to MMDx microarray test and central HLA antibody test . Principal investigator : Shelley Hall , MD , FACC , FHFSA , FAST .
For more information and a complete list of updated clinical trials : BRITrials . BSWSites . com .
Baylor Scott & White Heart and Vascular Hospital - Dallas | Advanced Heart Failure